



**2022 Project Summary for Placer Breast Cancer Foundation Fundraising Goal  
UC Davis Health  
UC Davis Comprehensive Cancer Center**

**Project:**

Triple Negative Breast Cancer Effective Treatments Study

**UC Davis Researcher:**

**Mili Arora, MD**

Assistant Clinical Professor

UC Davis Comprehensive Cancer Center

**Project Lay Summary**

Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and carries the worst prognosis, particularly at advanced stages. These cancers are complex and there are no FDA approved targetable therapies to treat this disease. Chemotherapy is the mainstay of treatment for TNBC but the required chemotherapy regimens are often toxic and short-lived. There is a tremendous need for novel therapies that are nontoxic. This project provides funds to study the feasibility of using a new combination of drugs to successfully battle TNBC. The results of this work show promise to assist in treating breast cancer patients with a more targeted and less toxic approach. In addition, it will have applications in several other types of breast cancer.

**Project Cost:**

\$175,000 over five years to provide support for the research (2018 through 2022).

**Goal:**

The Placer Breast Cancer Foundation is raising \$175,000 to fund to support the work to study the feasibility of using a new combination of drugs to successfully battle TNBC.